You are here

ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

Last updated on November 12, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Beijing, Beijing, 100029 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients enrolled should meet the usual prescribing criteria for Champix® as per
the local product information and should be entered into the trial at the
investigator's discretion

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- All patients enrolled should meet the usual prescribing criteria for Champix® as per
the local product information and should be entered into the trial at the
investigator's discretion

NCT00808015
Pfizer
Completed
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief TitleASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
Official TitleASIA CHOICES CHampix Observational Investigation in the CEssation of Smoking
Brief SummaryThe purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.
Detailed DescriptionSampling Method Description: Patients enrolled after being prescribed Champix for smoking cessation at the sole discretion of treating physician and patient.
Study TypeObservational
Study DesignObservational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationThis study is in Asian patients. The patients enrolled should be of legal adult age who regularly smoke and whose main tobacco product is cigarettes. The patients must be willing to make an attempt to stop smoking.
ConditionSmoking Cessation
InterventionDrug: varenicline
Champix will be prescribed as per usual practice and at the sole discretion of the physician
Other Name: Champix, Chantix
Study Groups/CohortsPatients in routine practice
Patients prescribed Champix by treating physician and then entered into trial
Intervention: Drug: varenicline
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: June 30, 2011)
1373
Original Estimated Enrollment
 (submitted: December 12, 2008)
1800
Actual Study Completion DateJuly 2010
Actual Primary Completion DateJuly 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion

Exclusion Criteria:

  • All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesChina,   India,   Korea, Republic of,   Philippines
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00808015
Other Study ID NumbersA3051112
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateApril 2015

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now